A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results

被引：4
|
作者：
O'Cearbhaill, R. E. [1 ,2 ]
Homicsko, K. [3 ,4 ]
Wolfer, A. [3 ,4 ]
DiSilvestro, P. A. [5 ]
O'Malley, D. M. [6 ,7 ]
Sabbatini, P. [1 ,2 ]
Orcurto, A. [3 ,4 ]
Barras, D. [3 ,4 ]
Shohara, L. [8 ]
Ricciardi, T. [8 ]
Macri, M. [8 ]
Ryan, A. [8 ]
Venhaus, R. R. [8 ]
Monk, B. J. [9 ,10 ]
Coukos, G. [11 ,12 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Univ Hosp, Lausanne, Switzerland
[4] Univ Lausanne, Lausanne, Switzerland
[5] Brown Univ, Women & Infants Hosp, Providence, RI USA
[6] Ohio State Univ, Coll Med, Arthur G James Canc Hosp, Columbus, OH 43210 USA
[7] Solove Res Inst, Columbus, OH USA
[8] Ludwig Canc Res, New York, NY USA
[9] Univ Arizona, Coll Med, US Oncol Network, Arizona Oncol, Phoenix, AZ USA
[10] Phoenix Creighton Univ, Sch Med, St Josephs Hosp, Phoenix, AZ USA
[11] Ludwig Canc Res, Lausanne, Switzerland
[12] Univ Hosp Lausanne, Lausanne, Switzerland
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷
关键词：
D O I：
10.1016/j.ygyno.2020.06.086
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
51
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [1] A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
    O'Cearbhaill, R. E.
    Wolfer, A.
    Disilvestro, P.
    O'Malley, D. M.
    Sabbatini, P.
    Shohara, L.
    Schwarzenberger, P. O.
    Ricciardi, T.
    Macri, M.
    Ryan, A.
    Venhaus, R. R.
    Bryan, J. K.
    Wong, P.
    Homicsko, K.
    Kandalaft, L.
    Rusakiewicz, S.
    Harari, A.
    Monk, B. J.
    Coukos, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results
    Street, Daron G.
    Kuttschreuter, Luke
    Starks, David
    Mahdi, Haider
    Linn, Carlos
    Pavlov, Dmitri
    Peguero, Julio Antonio
    Chawla, Sant P.
    Bruns, Ingmar
    Waggoner, Steven E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer
    Matulonis, U. A.
    Barry, W.
    Penson, R. T.
    Konstantinopoulos, P. A.
    Luo, W.
    Hoffman, M. A.
    Horowitz, N. S.
    Farooq, S.
    Dizon, D. S.
    Stover, E.
    Wright, A. A.
    Campos, S. M.
    Krasner, C.
    Liu, J. F.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 24 - 24
  • [4] Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer
    Verhaar-Langereis, M
    Karakus, A
    Van Eijkeren, M
    Voest, E
    Witteveen, E
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) : 65 - 70
  • [5] Efficacy and Toxicity of Gemcitabine and Pegylated Liposomal Doxorubicin in Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer
    Karaoglu, Aziz
    Arslan, Ulku Yalcintas
    Ozkan, Metin
    Kalender, Mehmet Emin
    Alici, Suleyman
    Coskun, Ugur
    Gumus, Mahmut
    Celenkoglu, Gokhan
    Er, Ozlem
    Sevinc, Alper
    Buyukberber, Suleyman
    Alkis, Necati
    Benekli, Mustafa
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2009, 10 (01) : 63 - 66
  • [6] Phase 1/2 Study of Atrasentan Combined with Pegylated Liposomal Doxorubicin in Platinum-Resistant Recurrent Ovarian Cancer
    Witteveen, Petronella O.
    van der Mijn, Koen J. C.
    Los, Maartje
    Kronemeijer, Roelien H.
    Groenewegen, Gerard
    Voest, Emile E.
    NEOPLASIA, 2010, 12 (11): : 941 - 945
  • [7] IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
    Wu, L.
    Wang, J.
    Wang, L.
    Lu, W.
    Wang, K.
    Lin, A.
    Li, N.
    Li, L.
    Su, N.
    Xie, S.
    Jiang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S516 - S516
  • [8] A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Shoji, Tadahiro
    Takatori, Eriko
    Omi, Hideo
    Kagabu, Masahiro
    Honda, Tatsuya
    Futagami, Masayuki
    Yokoyama, Yoshihito
    Kaiho, Michiko
    Tokunaga, Hideki
    Otsuki, Takeo
    Takano, Tadao
    Yaegashi, Nobuo
    Kojimahara, Takanobu
    Ohta, Tsuyoshi
    Nagase, Satoru
    Soeda, Shu
    Watanebe, Takafumi
    Nishiyama, Hiroshi
    Sugiyama, Toru
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (02) : 355 - 361
  • [9] A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
    Tadahiro Shoji
    Eriko Takatori
    Hideo Omi
    Masahiro Kagabu
    Tatsuya Honda
    Masayuki Futagami
    Yoshihito Yokoyama
    Michiko Kaiho
    Hideki Tokunaga
    Takeo Otsuki
    Tadao Takano
    Nobuo Yaegashi
    Takanobu Kojimahara
    Tsuyoshi Ohta
    Satoru Nagase
    Shu Soeda
    Takafumi Watanebe
    Hiroshi Nishiyama
    Toru Sugiyama
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 355 - 361
  • [10] A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
    Wu, Lingying
    Wang, Jing
    Wang, Li
    Lu, Weiguo
    Wang, Ke
    Lin, An
    Li, Ning
    Li, Li
    Su, Ning
    Xie, Shuang
    Jiang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345